Ole Andreas Andersen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ole Andreas Andersen has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Daan M. F. van Aalten
Section for Neurobiology and DANDRITE, Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark
12 shared publications - Ian M. Eggleston
Department of Life Sciences, University of Bath, Bath BA2 7AY, UK
11 shared publications Mark J. Dixon
A Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath Claverton Down, Bath, BA2 7AY, UK.; Fax: ++ 44 01225 386114
8 shared publicationsAmit Nathubhai
University of Bath
3 shared publicationsEdward Hough
3 shared publicationsFrancesco V. Rao
Division of Molecular Microbiology and Division of Biological Chemistry and Molecular Microbiology, College of Life Sciences, University of Dundee , Dow Street, Dundee, DD1 5EH, Scotland
3 shared publications
Latest Publications
- 27 January 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (3) , 1021-1046
Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s Disease
Tissue transglutaminase 2 (TG2) is a multifunctional protein primarily known for its calcium-dependent enzymatic protein cross-linking activity via isopeptide bond formation between glutamine and lysine residues. TG2 overexpression and activity have been found to be associated with Huntington’s disease (HD); specifically, TG2 is up-regulated in the brains of HD patients and in animal models of the disease. Interestingly, genetic deletion of TG2 in two different HD mouse models, R6/1 and R6/2, results in improved phenotypes including a reduction in neuronal death and prolonged survival. Starting with phenylacrylamide screening hit 7d, we describe the SAR of this series leading to potent and selective TG2 inhibitors. The suitability of the compounds as in vitro tools to elucidate the biology of TG2 was demonstrated through mode of inhibition studies, characterization of druglike properties, and inhibition profiles in a cell lysate assay.
- 27 January 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (3) , 1021-1046
Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s Disease
Tissue transglutaminase 2 (TG2) is a multifunctional protein primarily known for its calcium-dependent enzymatic protein cross-linking activity via isopeptide bond formation between glutamine and lysine residues. TG2 overexpression and activity have been found to be associated with Huntington’s disease (HD); specifically, TG2 is up-regulated in the brains of HD patients and in animal models of the disease. Interestingly, genetic deletion of TG2 in two different HD mouse models, R6/1 and R6/2, results in improved phenotypes including a reduction in neuronal death and prolonged survival. Starting with phenylacrylamide screening hit 7d, we describe the SAR of this series leading to potent and selective TG2 inhibitors. The suitability of the compounds as in vitro tools to elucidate the biology of TG2 was demonstrated through mode of inhibition studies, characterization of druglike properties, and inhibition profiles in a cell lysate assay.
- Open Access
- 1 May 2011
- Published by Elsevier in Chemistry & Biology
- Vol. 18 (5) , 569-579
Analyzing Airway Inflammation with Chemical Biology: Dissection of Acidic Mammalian Chitinase Function with a Selective Drug-like Inhibitor
- 1 May 2011
- Published by Elsevier in Chemistry & Biology
- Vol. 18 (5) , 569-579
Open AccessAnalyzing Airway Inflammation with Chemical Biology: Dissection of Acidic Mammalian Chitinase Function with a Selective Drug-like Inhibitor
- 23 March 2011
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 2 (6) , 428-432
Bisdionin C—A Rationally Designed, Submicromolar Inhibitor of Family 18 Chitinases
Chitinases of the GH18 family play important roles in a variety of pathogenic organisms and have also been shown to be involved in human asthma progression, making these enzymes potential drug targets. While a number of potent GH18 chitinase inhibitors have been described, in general, these compounds suffer from limited synthetic accessibility or unfavorable medicinal-chemical properties, making them poor starting points for the development of chitinase-targeted drugs. Exploiting available structural data, we have rationally designed bisdionin C, a submicromolar inhibitor of GH18 enzymes, that possesses desirable druglike properties and tractable chemical synthesis. A crystallographic structure of a chitinase-bisdionin C complex shows the two aromatic systems of the ligand interacting with two conserved tryptophan residues exposed in the active site cleft of the enzyme, while at the same time forming extensive hydrogen-bonding interactions with the catalytic machinery. The observed mode of binding, together with inhibition data, suggests that bisdionin C presents an attractive starting point for the development of specific inhibitors of bacterial-type, but not plant-type, GH 18 chitinases.
- 23 March 2011
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 2 (6) , 428-432
Bisdionin C—A Rationally Designed, Submicromolar Inhibitor of Family 18 Chitinases
Chitinases of the GH18 family play important roles in a variety of pathogenic organisms and have also been shown to be involved in human asthma progression, making these enzymes potential drug targets. While a number of potent GH18 chitinase inhibitors have been described, in general, these compounds suffer from limited synthetic accessibility or unfavorable medicinal-chemical properties, making them poor starting points for the development of chitinase-targeted drugs. Exploiting available structural data, we have rationally designed bisdionin C, a submicromolar inhibitor of GH18 enzymes, that possesses desirable druglike properties and tractable chemical synthesis. A crystallographic structure of a chitinase-bisdionin C complex shows the two aromatic systems of the ligand interacting with two conserved tryptophan residues exposed in the active site cleft of the enzyme, while at the same time forming extensive hydrogen-bonding interactions with the catalytic machinery. The observed mode of binding, together with inhibition data, suggests that bisdionin C presents an attractive starting point for the development of specific inhibitors of bacterial-type, but not plant-type, GH 18 chitinases.
- 17 July 2009
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section D Structural Biology
- Vol. 65 (8) , 872-874
Cross-linking of protein crystals as an aid in the generation of binary protein–ligand crystal complexes, exemplified by the human PDE10a–papaverine structure
Protein crystallography has proven to be an effective method of obtaining high-resolution structures of protein-ligand complexes. However, in certain cases only apoprotein structures are readily available and the generation of crystal complexes is more problematic. Some crystallographic systems are not amenable to soaking of ligands owing to crystal-packing effects and many protein-ligand complexes do not crystallize under the same conditions as used for the apoprotein. Using crystals of human phosphodiesterase 10a (hPDE10a) as an example of such a challenging crystallographic system, the structure of the complex with papaverine was obtained to 2.8 A resolution using protein crystals cross-linked by glutaraldehyde prior to soaking of the ligand. Inspection of the electron-density maps suggested that the correct mode of binding was obtained in one of the two monomers in the asymmetric unit and inspection of crystal-packing contacts explained why cocrystallization experiments and soaking of crystals that were not cross-linked were unsuccessful.
- 17 July 2009
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section D Structural Biology
- Vol. 65 (8) , 872-874
Cross-linking of protein crystals as an aid in the generation of binary protein–ligand crystal complexes, exemplified by the human PDE10a–papaverine structure
Protein crystallography has proven to be an effective method of obtaining high-resolution structures of protein-ligand complexes. However, in certain cases only apoprotein structures are readily available and the generation of crystal complexes is more problematic. Some crystallographic systems are not amenable to soaking of ligands owing to crystal-packing effects and many protein-ligand complexes do not crystallize under the same conditions as used for the apoprotein. Using crystals of human phosphodiesterase 10a (hPDE10a) as an example of such a challenging crystallographic system, the structure of the complex with papaverine was obtained to 2.8 A resolution using protein crystals cross-linked by glutaraldehyde prior to soaking of the ligand. Inspection of the electron-density maps suggested that the correct mode of binding was obtained in one of the two monomers in the asymmetric unit and inspection of crystal-packing contacts explained why cocrystallization experiments and soaking of crystals that were not cross-linked were unsuccessful.
- 17 June 2009
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 23 (8) , 459-473
The multiple roles of computational chemistry in fragment-based drug design
Fragment-based drug discovery (FBDD) represents a change in strategy from the screening of molecules with higher molecular weights and physical properties more akin to fully drug-like compounds, to the screening of smaller, less complex molecules. This is because it has been recognised that fragment hit molecules can be efficiently grown and optimised into leads, particularly after the binding mode to the target protein has been first determined by 3D structural elucidation, e.g. by NMR or X-ray crystallography. Several studies have shown that medicinal chemistry optimisation of an already drug-like hit or lead compound can result in a final compound with too high molecular weight and lipophilicity. The evolution of a lower molecular weight fragment hit therefore represents an attractive alternative approach to optimisation as it allows better control of compound properties. Computational chemistry can play an important role both prior to a fragment screen, in producing a target focussed fragment library, and post-screening in the evolution of a drug-like molecule from a fragment hit, both with and without the available fragment-target co-complex structure. We will review many of the current developments in the area and illustrate with some recent examples from successful FBDD discovery projects that we have conducted.
- 17 June 2009
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 23 (8) , 459-473
The multiple roles of computational chemistry in fragment-based drug design
Fragment-based drug discovery (FBDD) represents a change in strategy from the screening of molecules with higher molecular weights and physical properties more akin to fully drug-like compounds, to the screening of smaller, less complex molecules. This is because it has been recognised that fragment hit molecules can be efficiently grown and optimised into leads, particularly after the binding mode to the target protein has been first determined by 3D structural elucidation, e.g. by NMR or X-ray crystallography. Several studies have shown that medicinal chemistry optimisation of an already drug-like hit or lead compound can result in a final compound with too high molecular weight and lipophilicity. The evolution of a lower molecular weight fragment hit therefore represents an attractive alternative approach to optimisation as it allows better control of compound properties. Computational chemistry can play an important role both prior to a fragment screen, in producing a target focussed fragment library, and post-screening in the evolution of a drug-like molecule from a fragment hit, both with and without the available fragment-target co-complex structure. We will review many of the current developments in the area and illustrate with some recent examples from successful FBDD discovery projects that we have conducted.
- 1 January 2009
- Published by Springer Nature
- Vol. 611, 143-144
SPPS of the Natural Product Chitinase Inhibitor Argifin: Library Generation and Biological Evaluation
- 1 January 2009
- Published by Springer Nature
- Vol. 611, 143-144
SPPS of the Natural Product Chitinase Inhibitor Argifin: Library Generation and Biological Evaluation
- 1 January 2009
- Published by Springer Nature
- Vol. 611, 525-526
Synthesis and Structure-based Dissection of Cyclic Peptide Chitinase Inhibitors: New Leads for Antifungal and Anti-Inflammatory Drugs
- 1 January 2009
- Published by Springer Nature
- Vol. 611, 525-526
Synthesis and Structure-based Dissection of Cyclic Peptide Chitinase Inhibitors: New Leads for Antifungal and Anti-Inflammatory Drugs
- Open Access
- 1 January 2009
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 7 (2) , 259-268
Solid-phase synthesis of cyclic peptide chitinase inhibitors: SAR of the argifin scaffold
An efficient, all-solid-phase synthesis of argifin, a cyclic peptide chitinase inhibitor with chemotherapeutic potential, is described.
- 1 January 2009
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 7 (2) , 259-268
Open AccessSolid-phase synthesis of cyclic peptide chitinase inhibitors: SAR of the argifin scaffold
An efficient, all-solid-phase synthesis of argifin, a cyclic peptide chitinase inhibitor with chemotherapeutic potential, is described.
- Open Access
- 1 March 2008
- Published by Elsevier in Chemistry & Biology
- Vol. 15 (3) , 295-301
Structure-Based Dissection of the Natural Product Cyclopentapeptide Chitinase Inhibitor Argifin
- 1 March 2008
- Published by Elsevier in Chemistry & Biology
- Vol. 15 (3) , 295-301
Open AccessStructure-Based Dissection of the Natural Product Cyclopentapeptide Chitinase Inhibitor Argifin
- Open Access
- 29 March 2007
- Published by Springer Nature in The EMBO Journal
- Vol. 26 (8) , 2206-2217
Structural basis for enzymatic excision of N1‐methyladenine and N3‐methylcytosine from DNA
N 1‐methyladenine (m1A) and N 3‐methylcytosine (m3C) are major toxic and mutagenic lesions induced by alkylation in single‐stranded DNA. In bacteria and mammals, m1A and m3C were recently shown to be repaired by AlkB‐mediated oxidative demethylation, a direct DNA damage reversal mechanism. No AlkB gene homologues have been identified in Archaea. We report that m1A and m3C are repaired by the Af AlkA base excision repair glycosylase of Archaeoglobus fulgidus , suggesting a different repair mechanism for these lesions in the third domain of life. In addition, Af AlkA was found to effect a robust excision of 1, N 6‐ethenoadenine. We present a high‐resolution crystal structure of Af AlkA, which, together with the characterization of several site‐directed mutants, forms a molecular rationalization for the newly discovered base excision activity.
- 29 March 2007
- Published by Springer Nature in The EMBO Journal
- Vol. 26 (8) , 2206-2217
Open AccessStructural basis for enzymatic excision of N1‐methyladenine and N3‐methylcytosine from DNA
N 1‐methyladenine (m1A) and N 3‐methylcytosine (m3C) are major toxic and mutagenic lesions induced by alkylation in single‐stranded DNA. In bacteria and mammals, m1A and m3C were recently shown to be repaired by AlkB‐mediated oxidative demethylation, a direct DNA damage reversal mechanism. No AlkB gene homologues have been identified in Archaea. We report that m1A and m3C are repaired by the Af AlkA base excision repair glycosylase of Archaeoglobus fulgidus , suggesting a different repair mechanism for these lesions in the third domain of life. In addition, Af AlkA was found to effect a robust excision of 1, N 6‐ethenoadenine. We present a high‐resolution crystal structure of Af AlkA, which, together with the characterization of several site‐directed mutants, forms a molecular rationalization for the newly discovered base excision activity.